RTP Mobile Logo
Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Multiple Myeloma
Released March 2014

Proceedings from Part 2 of a 2-part satellite symposia series during the 55th ASH Annual Meeting. Featuring perspectives from Drs Amrita Krishnan, A Keith Stewart, William I Bensinger, Meletios A Dimopoulos and Noopur Raje. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

    OVERVIEW OF ACTIVITY

    It is estimated that approximately 22,350 new cases of MM were identified in the United States in the year 2013, and 10,710 individuals died from the disease. Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to longstanding clinical questions. As these trials reach their maturity, clinical investigators seek opportunities to present this information publicly so that relevant findings can be quickly incorporated into future research and current patient care. Although the extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies.

    These proceedings from a CME symposium during the 55th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology to frame a relevant discussion of the optimal management of MM. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for MM.


    LEARNING OBJECTIVES
    • Appraise recent data on therapeutic advances and changing practice standards in MM, and integrate this information, when appropriate, into current clinical care.
    • Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
    • Identify patients with MM who may benefit from maintenance systemic treatment in both the post-transplant and nontransplant settings.
    • Develop a risk-adapted treatment plan for patients with smoldering myeloma, considering the roles of observation and active treatment.
    • Recall new data with investigational agents demonstrating promising activity in MM.
    • Assess the ongoing clinical trials evaluating innovative investigational approaches for MM, and obtain consent from appropriate patients for study participation.
    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Amrita Krishnan, MD
    Director, Multiple Myeloma Program
    City of Hope Cancer Center
    Duarte, California

    Advisory Committee: Celgene Corporation, Onyx Pharmaceuticals Inc; Ownership Interest: Celgene Corporation; Speakers Bureau: Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

    A Keith Stewart, MBChB
    Dean for Research, Mayo Clinic in Arizona
    Consultant, Division of Hematology/Oncology
    Vasek and Anna Maria Polak Professorship in Cancer Research
    Scottsdale, Arizona

    Advisory Committee: Amgen Inc, Celgene Corporation; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; Contracted Research: Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

    William I Bensinger, MD
    Professor of Medicine, University of Washington
    Member, Fred Hutchinson Cancer Research Center
    Director, Autologous Stem Cell Transplant Program
    Seattle, Washington

    Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi; Consulting Agreement: Celgene Corporation; Contracted Research: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation.

    Meletios A Dimopoulos, MD
    Chairman, Department of Medical Therapeutics
    University of Athens School of Medicine
    Athens, Greece

    Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.


    Noopur Raje, MD
    Director, Center for Multiple Myeloma
    Massachusetts General Hospital Cancer Center
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Amgen Inc, Celgene Corporation; Consulting Agreements: Lilly, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Contracted Research: Acetylon Pharmaceuticals Inc, Amgen Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Lilly, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection

    A monitor set to 1280 x 1024 pixels or more

    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

    Adobe Flash Player 10.2 plug-in or later

    Adobe Acrobat Reader

    (Optional) Sound card and speakers for audio

    Last review date: March 2014
    Expiration date: March 2015

Acknowledge and close

View video: